NEW YORK, August 14, 2025--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback